[Skip to Content]
[Skip to Content Landing]
September 22/29, 2004

Intravenous Immunoglobulin and Quality of Life

JAMA. 2004;292(12):1429-1430. doi:10.1001/jama.292.12.1429-a

To the Editor: The clinical review by Dr Dalakas1 underscores that intravenous immunoglobulin (IVIG) is the treatment of choice in Guillain-Barré syndrome (GBS), multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy (CIDP) and that it is useful instead of plasma exchange for management of myasthenia gravis. On the other hand, he stresses the necessity of further studies of dose-finding effects, pharmacoeconomics, and quality of life (QOL) assessments to improve the evidence base for clinical practice.

First Page Preview View Large
First page PDF preview
First page PDF preview